The Diagnostic Technology Applied Research of CDK5RAP2 in Breast Cancer

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01634984

Enrollment

500

Registered

2012-07-06

Start date

2012-01-31

Completion date

2016-12-31

Last updated

2015-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

expression of CDK5RAP2

Brief summary

Selected 400 cases of women with primary breast cancer who were treated with operation randomly, then detect the expression of CDK5RAP2 of cancer tissue. At the same time randomly selected 100 women with primary breast cancer who were under neoadjuvant chemotherapy. Detect the expression of CDK5RAP2 before and after neoadjuvant chemotherapy.

Detailed description

The investigators selected 400 cases of women with primary breast cancer who were treated with operation randomly,then detect the expression of CDK5RAP2 of cancer tissue. At the same time randomly selected 100 women with primary breast cancer who were under neoadjuvant chemotherapy. Detect the expression of CDK5RAP2 before and after neoadjuvant chemotherapy.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

1. Provision of informed consent 2. Pathological confirmation of breast cancer 3. Tumor stage(TNM):T2-4bN0-3M0 4. ER(+) and/or PR(+). 5. Premenopausal woman. 6. Age≥40 years 7. Measurable disease as per RECIST criteria 8. Karnofsky≥70 9. Laboratory criteria: * PLT≥100\*109/L * WBC≥4000/mm3 * HGB≥10g/dl * ALT and AST\<2\*ULN

Exclusion criteria

1. Presence of metastatic disease. 2. Inflammatory breast cancer. 3. Bilateral breast cancer. 4. previous chemotherapy or hormonal therapy for current breast neoplasm. 5. other malignant tumor (concurrent or previous). 6. Pregnant woman. 7. Hypersensitive to any drug in CEF regimen or any ingredient of Zoladex. 8. Any severe systemic disease contraindicating chemotherapy.

Countries

China

Contacts

Primary ContactJin Zhang, Pro.

davidz9132002@yahoo.com86-022-23340123

Outcome results